The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation

American Journal of Kidney Diseases

Volumn 29, Issue 3, 1997, Pages 428-434

  Schnitzler, Mark A ^a   Woodward, Robert S ^b   Brennan, Daniel C ^b   Spitznagel, Edward L ^b   Dunagan, William C ^b   Bailey, Thomas C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

cytomegalovirus; multivariate survival analysis; Renal transplantation

Indexed keywords

ARTICLE; CADAVER KIDNEY; CONTROLLED STUDY; CYTOMEGALOVIRUS; GRAFT SURVIVAL; HUMAN; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; RECIPIENT; RESOURCE ALLOCATION; SEROLOGY; STATISTICAL ANALYSIS; SURVIVAL;

EID: 0031042877     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90205-5     Document Type: Article

References (23)

1. Rubin RH: Infection in the renal and liver transplant patient, in Rubin RH, Young LS (eds): Clinical Approach to Infection in the Compromised Host (ed 2). New York, NY, Plenum Medical Books, 1988, pp 557-621
2. Gjertson DW: Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry: A 1994 update, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1994,.Los Angeles, CA, UCLA Tissue Typing Laboratory, 1995, pp 519-539.
3. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH Jr, Najarian JS: Cytomegalovirus as a risk factor in renal transplantation. Transplantation 3:436-439, 1980
4. Richardson WP, Colvin RB, Cheeseman SH, Tolkoff-Rubin NE, Herrin JT, Cosimi AB, Collins AB, Hirsch MS, McCluskey RT, Russell PS, Rubin RH: Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 305:57-63, 1981
5. Grundy JE, Ayles HM, McKeating JA, Butcher RG, Griffiths PD, Poulter LW: Enhancement of class I antigen expression by cytomegalovirus: Role of amplification of virus infection. J Med Virol 25:483-495, 1988
6. Von Willebrand E, Pettersson E, Ahonen J, Hayry P: CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 42:364-367, 1986
7. Fujinami RS, Nelson JA, Walker L, Oldstone MB: Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: A means for graft rejection and immunosuppression. J Virol 62:100-105, 1988
8. Beck S, Barrell BG: Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 331:269-272, 1988
9. Chou S: Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 314:1418-1423, 1986
10. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, Moorhead J, Griffiths PD: Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2:132-135, 1988
11. Sharples LD, Scott JP, Dennis C, Higenbottam TW, Stewart S, Wreghitt T, Large SR, Wells FC, Wallwork J: Risk factors for survival following combined heart-lung transplantation: The first 100 patients. Transplantation 57:218-223, 1994
12. Sutherland S, Bracken P, Wreghitt TG, O'Grady J, Calne RY, Williams R: Donated organ as a source of cytomegalovirus in orthotopic liver transplantation. J Med Virol 37:170-173, 1992
13. Chou S, Norman DJ: The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients. Transplantation 46:89-93, 1988
14. Smiley ML, Wlodaver CG, Grossman RA, Barker CF, Perloff LJ, Tustin NB, Starr SE, Plotkin SA, Friedman HM: The role of pretransplant immunity in protection from cytomegalovirus disease following transplantation. Transplantation 40:157-161, 1985
15. Ackerman JR, LeFor WM, Weinstein S, Kahana L, Shires DL, Tardif G, Baxter J: Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients. Transplant Proc 20:469-471, 1988
16. Henell KR, Chou S, Norman DJ: Use of cytomegalovirus seropositive kidneys in seronegative patients: Results of prospective serotesting and matching in one center. Transplant Proc 21:2082-2083, 1989
17. Williams PF, Wreghitt T, Joysey V, Evans DB, Calne RY: Cytomegalovirus matching in renal transplantation. Lancet 2:569, 1988
18. Shackleton CR, Keown PA, Landsberg DN, McCarthy JM, Scudamore CH, Kane LM, Cameron EC, Yeung CK, Chiu AS: The impact of donor/recipient matching for cytomegalovirus compatibility or identity on the incidence of disease and outcome following renal transplantation. Transplant Proc 23:1350-1351, 1991
19. Morris DJ, Martin S, Dyer PA, Hunt L, Mallick NP, Johnson RW: HLA mismatching and Cytomegalovirus infection as risk factors for transplant failure in cyclosporinetreated renal allograft recipients. J Med Virol 41:324-327, 1993
20. Crumpacker CS: Ganciclovir. N Engl J Med 335:721-729, 1996
21. US Renal Data System: Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
22. Judge GG, Hill RC, Griffiths WE, Lutkepohl H, Tsoung-Chao L: Introduction to the Theory and Practice of Econometrics (ed 2). New York, NY, Wiley, 1988, pp 582-585
23. Gane E, Saliba F, Baldecasas G, O'Grady J, Behrend M, Pescovitz MD, Pruett T, Hockerstedt K, Broelsch C, Mino-Fugaolas G, Houssin D, Davis C, Henry M, Erhard J, Kam I, King P, Robinson CA. Ganciclovir International Transplantation Study Group. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: Results of a multicenter multinational clinical trial. Dallas, TX, ASTP Meetings 171:26-30, 1996 (abstr 346)